Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Donor-recipient sex matching for red blood cell transfusions in adult ICU patients

Official title: Effects of Donor-recipient Sex-matched Versus Sex-mismatched Red Blood Cell Transfusion on Outcomes in Critically Ill Adult Patients

Run by McMaster University · NCT06840756 · Data updated 2026-11-12

We will test whether giving adult ICU patients red blood cell transfusions from donors of the same sex improves survival compared with transfusions from donors of the opposite sex.

More Cardiovascular Disease trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment11082 (estimated)
SponsorMcMaster University
Academic / other
Locations8 sites (Hamilton, Ontario and 7 other locations)
StatusRecruiting
StartedSeptember 11, 2025
Main results expectedDecember 31, 2028
Study endsMarch 31, 2029
Registry record updatedMarch 12, 2026
Trial IDNCT06840756 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (age ≥18) admitted to a participating ICU who require a red blood cell transfusion and have a valid Ontario health card are eligible to join.

Probably not a fit

Patients who are massively bleeding, require specialized or rare blood products, or whose sex is unknown or is not male/female are not eligible and would not receive potential benefit from this matching strategy.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, pragmatic, phase 4 randomized controlled trial enrolling adults admitted to participating intensive care units who require a red blood cell transfusion. Participants are randomized to receive either sex-matched or sex-mismatched donor red blood cell units, with common exclusions such as massive hemorrhage, need for specialized/rare RBC products, or unknown/non-binary sex. The trial builds on prior observational analyses, a pilot RCT, and biological data suggesting a possible benefit from sex-matching, and is powered to compare mortality and clinical outcomes between groups. The protocol is being conducted across several Ontario teaching hospitals with CIHR-supported oversight.

Why it matters

Potential benefit: If successful, sex-matching donor and recipient red blood cell transfusions could reduce deaths and transfusion-related complications in ICU patients who need transfusions.

How similar studies have gone: Observational studies and a large exploratory analysis have suggested a signal of benefit and emerging biological plausibility, but results have been mixed and a definitive large randomized trial has not yet confirmed benefit.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults (age ≥18);
* Admission to a participating ICU;
* Requiring RBC transfusion.

Exclusion Criteria:

* Requirement for a specialized RBC product or unit not readily available in inventory (e.g., rare blood type, washed RBCs, complex RBC antibodies, etc.);
* Massively bleeding patient (i.e., ≥4 units of blood ordered at one time, or Massive Hemorrhage Protocol initiated, or an urgent blood request made);
* Sex unknown or sex other than male or female (i.e. intersex);
* Do not have a valid Ontario Health Insurance Plan (OHIP) health card number.

Where it's running

  • Hamilton General Hospital
    Hamilton, Ontario, Canada
    Recruiting
  • Kingston Health Sciences Centre
    Kingston, Ontario, Canada
    Not yet recruiting
  • London Health Sciences Centre
    London, Ontario, Canada
    Not yet recruiting
  • Lakeridge Health Oshawa
    Oshawa, Ontario, Canada
    Not yet recruiting
  • The Ottawa Hospital
    Ottawa, Ontario, Canada
    Not yet recruiting
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
    Not yet recruiting
Show 2 more locations
  • Mount Sinai Hospital
    Toronto, Ontario, Canada
    Not yet recruiting
  • Toronto General Hospital
    Toronto, Ontario, Canada
    Not yet recruiting

Study contacts

  • Principal investigator: Michelle Zeller, Doctor of Medicine — McMaster University
  • Study coordinator: Michelle Zeller, Doctor of Medicine
  • Email: zeller@mcmaster.ca
  • Phone: 1-905-525-9140

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.